Systemic lupus erythematosus (lupus) is a complex autoimmune disease that involves major components of the immune system. It has heterogeneous clinical manifestations and, at the earliest stages, it is characterized by a deficiency of IL-2 and TGF-b, (1, 2), and epigenetic abnormalities that include an abnormal development and stability of CD4 + CD25 + CD127 low T regulatory (Treg) cells (3). However, merely enumerating the levels of circulating Treg cells in lupus patients has yielded inconsistent results because some of those Treg cells are functionally inactive (4, 5), and Treg cells directed to major autoantigens of lupus are not detectable in patients with active disease (6) and Robinson et al. Therefore, generating stable Treg cells that preferentially suppress pathogenic activity of self-reactive immune cells represents a critical therapeutic goal for the modulation of lupus disease, as discussed in this Research Topic.Datta reviews the origins of the first experiments that showed that an endogenous self-antigen, namely nucleosomes from apoptotic cells, linked self-reactive lupus T helper (Th) and B cell with cognate interactions leading to the production of class-switched nephritogenic anti-dsDNA autoantibodies. Subsequently, minute doses of certain histone peptide epitopes from nucleosomes were found to induce autoantigen-specific CD4 + and CD8 + Treg cells. Surprisingly the epitopes were also found to render dendritic cells tolerogenic directly, which led to inhibition of multiple autoreactive cells participating in pathogenic autoimmune response in lupus.Wei et al. review cellular mechanisms that lead to production of high-affinity autoantibodies in SLE. The onset of autoantibodies in systemic autoimmunity requires a complex and highly regulated B-T cell functional crosstalk as well as mature germinal center (GC) formation in B cell follicles of secondary lymphoid tissues. A key regulator of such events is the T follicular regulatory cell (TFR), a specialized Treg cell population that protects from hyperactivity of self-reactive T and B cells. However, recent studies show that TFRs manifest functional plasticity as they can lose Foxp3 expression and convert into disease-promoting "ex-TFRs" that acquire potent effector/